GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VBI Vaccines Inc (NAS:VBIV) » Definitions » PS Ratio

VBI Vaccines (VBI Vaccines) PS Ratio : 1.29 (As of May. 15, 2024)


View and export this data going back to 2016. Start your Free Trial

What is VBI Vaccines PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, VBI Vaccines's share price is $0.6301. VBI Vaccines's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.49. Hence, VBI Vaccines's PS Ratio for today is 1.29.

Good Sign:

VBI Vaccines Inc stock PS Ratio (=1.14) is close to 10-year low of 1.07

The historical rank and industry rank for VBI Vaccines's PS Ratio or its related term are showing as below:

VBIV' s PS Ratio Range Over the Past 10 Years
Min: 1.07   Med: 200.79   Max: 1067.44
Current: 1.29

During the past 13 years, VBI Vaccines's highest PS Ratio was 1067.44. The lowest was 1.07. And the median was 200.79.

VBIV's PS Ratio is ranked better than
90.09% of 999 companies
in the Biotechnology industry
Industry Median: 9.04 vs VBIV: 1.29

VBI Vaccines's Revenue per Sharefor the three months ended in Dec. 2023 was $0.04. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.49.

Warning Sign:

VBI Vaccines Inc revenue per share has been in decline for the last 5 years.

During the past 12 months, the average Revenue per Share Growth Rate of VBI Vaccines was 342.90% per year. During the past 3 years, the average Revenue per Share Growth Rate was 56.30% per year. During the past 5 years, the average Revenue per Share Growth Rate was -25.30% per year.

During the past 13 years, VBI Vaccines's highest 3-Year average Revenue per Share Growth Rate was 56.30% per year. The lowest was -63.60% per year. And the median was -37.10% per year.

Back to Basics: PS Ratio


VBI Vaccines PS Ratio Historical Data

The historical data trend for VBI Vaccines's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VBI Vaccines PS Ratio Chart

VBI Vaccines Annual Data
Trend Mar14 Mar15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 74.19 565.07 948.65 93.12 1.05

VBI Vaccines Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 93.12 54.43 15.59 1.37 1.05

Competitive Comparison of VBI Vaccines's PS Ratio

For the Biotechnology subindustry, VBI Vaccines's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


VBI Vaccines's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VBI Vaccines's PS Ratio distribution charts can be found below:

* The bar in red indicates where VBI Vaccines's PS Ratio falls into.



VBI Vaccines PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

VBI Vaccines's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=0.6301/0.489
=1.29

VBI Vaccines's Share Price of today is $0.6301.
VBI Vaccines's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.49.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


VBI Vaccines  (NAS:VBIV) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


VBI Vaccines PS Ratio Related Terms

Thank you for viewing the detailed overview of VBI Vaccines's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


VBI Vaccines (VBI Vaccines) Business Description

Traded in Other Exchanges
Address
160 Second Street, Floor 3, Cambridge, MA, USA, 02142
VBI Vaccines Inc is a US-based commercial-stage, the biopharmaceutical company which is engaged in developing next-generation vaccines to address unmet needs in infectious disease and immuno-oncology. The company manufactures Sci-B-Vac product which is a hepatitis B (HBV) vaccine for adults, children, and newborns. Its products include Virus-Like Particle which is vaccine platform which allows for the design of enveloped virus-like particle vaccines that closely mimic the target viruses. The company operates through the single segment being Developing vaccines to address unmet needs in infectious disease and immuno-oncology.
Executives
Steven Gillis director 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Vaughn B Himes director C/O SEATTLE GENETICS, INC., 21823 30TH DRIVE SE, BOTHELL WA 98021
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
John Robert Dillman officer: Chief Commercial Officer C/O VBI VACCINES INC., 160 SECOND STREET, FLOOR 3, CAMBRIDGE MA 02142
Nell Beattie officer: Director, Corp Development/IR 222 THIRD STREET, SUITE 2241, CAMBRIDGE MA 02142
Linda Bain director C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Damian Braga director 222 THIRD STREET, SUITE 2241, CAMBRIDGE MA 02142
Francisco Diaz-mitoma officer: Chief Medical Officer 222 THIRD STREET, SUITE 2241, CAMBRIDGE MA 02142
Christopher Mcnulty officer: CFO and Head of BD C/O INVIVO THERAPEUTICS HOLDINGS CORP., 1 KENDALL SQUARE, SUITE B14402, CAMBRIDGE MA 02139
Jeff Baxter director, officer: President and CEO C/O VBI VACCINES INC.,, 222 THIRD STREET, STE 2241, CAMBRIDGE MA 02142
Joanne Cordeiro director 171 SWANTON STREET, UNIT 48, WINCHESTER MA 01890
Blaine H. Mckee director C/O HART, 84 OCTOBER HILL ROAD, SUITE 11, HOLLISTON MA 01746
Tomer Kariv director C/O ARNO THERAPEUTICS, INC., 200 ROUTE 31 NORTH, SUITE 104, FLEMINGTON NJ 08822
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003